Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 7Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Multiple Myeloma 4Lymphoma 4Endometrial Neoplasms 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Neoplasm Metastasis 2Hereditary Sensory and Autonomic Neuropathies 2Hematologic Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Recurrent Malignant Solid Neoplasm 1Recurrent Lung Squamous Cell Carcinoma 1Recurrence 1

Interventions

Cyclophosphamide 217Rituximab 110Etoposide 99Peripheral Blood Stem Cell Transplantation 94Vincristine 91Filgrastim 91Cytarabine 91Methotrexate 90fludarabine phosphate 85Radiotherapy 67Doxorubicin 67Prednisone 66Dexamethasone 57Mycophenolic Acid 53Cyclosporine 53Whole-Body Irradiation 50Busulfan 47Melphalan 44blinatumomab 43Tacrolimus 42fludarabine 41Antilymphocyte Serum 40Methylprednisolone 39merphos 35Calcium Dobesilate 34Leucovorin 33Granulocyte Colony-Stimulating Factor 30Mercaptopurine 26dexamethasone acetate 25dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × sapanisertib × Clear all
NCT02484430 2025-03-03

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡